RobertMLangdonMD

Oncology • Omaha, NE

Physician

Join to view full profile

Dr. Langdon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Langdon's full profile

Already have an account?

Office
8303 Dodge St
Suite 250
Omaha, NE 68114
Phone+1 402-354-8127

Fax+1 402-354-8127
Is this information wrong?

Summary

Dr. Robert Langdon is an oncologist in Omaha, NE and is affiliated with multiple hospitals in the area, including CHI Health Creighton University Medical Center - Bergan Mercy, CHI Health Immanuel, CHI Health Creighton University Medical Center, and Nebraska Methodist Hospital. He received his medical degree from University of Nebraska College of Medicine and has been in practice 38 years. He specializes in hematologic oncology and is experienced in hematologic oncology and hospice and palliative care.

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1982 - 1984
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1979 - 1982
University of Nebraska College of MedicineClass of 1979

Certifications & Licensure

CO State Medical License 2008 - 2025
IA State Medical License 1979 - 2025
NE State Medical License 1984 - 2024
IL State Medical License 1982 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FASCO) American Society of Clinical Oncologists, 2008
Fellow (FACP) American College of Physicians, 2003

Clinical Trials

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Completed
Phase 2
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy Start of enrollment: 2013 Feb 01
Completed
Early Phase 1
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

26 citations
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
John D. Hainsworth, Kevin P. Becker, Tarek Mekhail, Sajeel A. Chowdhary, Janice Faulkner Eakle, David Wright, Robert M. Langdon, Kathleen Yost, Gilbert Darin Anthony P...> ;Journal of Neuro-Oncology. 2019 Aug 7
439 citations
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper, Nancy E. Davidson, Dana S. Wollins, Douglas W. Blayney, Adam P. Dicker, Patricia A. Ganz, J. Russell Hoverman, Robert M. Langdon, Gary H. Lyman, N...> ;Journal of Clinical Oncology. 2016 Sep 27
46 citations
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer wi...
Cathy Eng, Alberto Bessudo, Lowell L. Hart, Aleksey Severtsev, Oleg Gladkov, Lothar Müller, Mikhail V. Kopp, Vladimir Ivanovich Vladimirov, Robert M. Langdon, Bogdan K...> ;International Journal of Cancer. 2016 Jul 1
58 citations
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose, Wael A. Harb, Leo I. Gordon, Robert M. Langdon, Julian Sprague, Mint Sirisawad, Chitra Mani, Jeanne Yue, Ying L...> ;Clinical Cancer Research. 2016 Mar 1
648 citations
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper, Nancy E. Davidson, Dana S. Wollins, Courtney Tyne, Douglas W. Blayney, Diane Blum, Adam P. Dicker, Patricia A. Ganz, J. Russell Hoverman, Robert M...> ;Journal of Clinical Oncology. 2015 Jun 22
Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study.
O'Dorisio TM, Phan AT, Langdon RM, Marek BJ, Ikhlaque N, Bergsland EK, Freiman J, Law L, Banks PL, Frazier K, Jackson J, Zambrowicz B, Kulke M> ;J. Clin. Oncol.. 2012-02-01
A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with refractory symptom...
Kulke M, O'Dorisio TM, Phan AT, Langdon RM, Marek BJ, Iklaque N, Bergsland EK, Freiman J, Frazier K, Jackson J, Zambrowicz B> ;J. Clin. Oncol.. 2011-05-20
445 citations
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Neal J. Meropol, Deborah Schrag, Thomas J. Smith, Therese M. Mulvey, Robert M. Langdon, Diane Blum, Peter A. Ubel, Lowell E. Schnipper> ;Journal of Clinical Oncology. 2009 Aug 10
48 citations
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic ...
Noah M. Hahn, Sharon Marsh, William E. Fisher, Robert M. Langdon, Robin Zon, Mark Browning, Cynthia S. Johnson, TJ Scott-Horton, Lang Li, Howard L. McLeod, Christopher...> ;Clinical Cancer Research. 2006 Oct 15
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Dy GK, Miller AA, Mandrekar SJ, Aubry M, Langdon RM, Morton RF, Schild SE, Jett JR, Adjei AA> ;Ann. Oncol.. 2005-11-01
A multicenter randomized phase II study of docetaxel (D) plus vinorelbine (VRB) and docetaxel plus estramustine (EMP) in combination for the treatment of hormone refra...
Hahn NM, Fisher W, Langdon R, Zon R, Mark B, Sweeney CJ> ;J. Clin. Oncol.. 2005-06-01
A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit-expressing relapsed small cell lung cancer (SCLC).
Dy GK, Miller AA, Mandrekar S, Aubry M, Langdon RM, Schild SE, Jett JR, Adjei AA> ;J. Clin. Oncol.. 2005-06-01
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.
Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM, Kugler J, Rodrigue LJ> ;J. Clin. Oncol.. 1995-11-01
44 citations
Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation
Julie M. Vose, James O. Armitage, Philip J. Bierman, Dennis D. Weisenburger, Mark Hutchins, Monroe D. Dowling, Daniel F. Moravec, Scot Sorensen, John A. Okerbloom, Geo...> ;The American Journal of Medicine. 1989 Sep 1
185 citations
Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases
Kathy Foucar, Robert M. Langdon, James O. Armitage, Daniel B. Olson, Thomas J. Carroll> ;Cancer. 1985 Aug 1
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Fellow
American College of Physicians - ACP
Fellow

Hospital Affiliations

CHI Health Creighton University Medical Center - Bergan MercyOmaha, Nebraska
CHI Health ImmanuelOmaha, Nebraska
CHI Health Creighton University Medical CenterOmaha, Nebraska
Nebraska Methodist HospitalOmaha, Nebraska